Now showing items 1-2 of 2
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
(Kluwer Academic Publishers; Springer Science+Business Media, 2004-11)
Objectives : CCI-779 is an ester of the immunosuppressive agent sirolimus (rapamycin) that causes cell-cycle arrest at G1 via inhibition of key signaling pathways resulting in inhibition of RNA translation. Antitumor ...
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
(Kluwer Academic Publishers; Springer Science + Business Media, Inc., 2005-08)
Purpose : Loss of PTEN, which is common in glioblastoma multiforme (GBM), results in activation of the mammalian target of rapapmycin (mTOR), thereby increasing mRNA translation of a number of key proteins required for ...